Abstract
The report of Cummins et al. (Pediatrics 59:144, January 1977) is of potential clinical importance. Additional information, however, would make their data easier to interpret.
Erythromycin is marketed as the free base and as various salts. Only erythromycin estolate has been demonstrated to have hepatotoxic potential. Since troleandomycin, another macrolide antibiotic with even greater hepatotoxic potential, has a profound effect on theophylline clearance, probably by decreasing hepatic metabolism,1 the highest index of suspicion for a similar interaction with an erythromycin would be directed at the potentially hepatotoxic estolate salt (Ilosone).
- Copyright © 1978 by the American Academy of Pediatrics
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.